医学临床研究
  2025年7月22日 星期二           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (12): 1885-1888    DOI: 10.3969/j.issn.1671-7171.2023.12.018
  论著 本期目录 | 过刊浏览 | 高级检索 |
BEP与ACM化疗方案治疗滋养细胞肿瘤患者的疗效对比
刘利英, 翟瑶*, 张恒瑜
陕西省核工业二一五医院妇科,陕西 咸阳 712000
Comparison of the Efficacy of BEP and ACM Chemotherapy Regimens in the Treatment of Patients with Trophoblastic Tumors
LIU Liying, ZHAI Yao, ZHANG Hengyu
Department of Gynecology, NO.215 Hospital of Shaanxi Nuclear Industry,Xianyang Shaanxi 712000
全文: PDF (1242 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】对比博莱霉素(BLM)、依托泊苷(VP-16)、顺铂(DDP)联合化疗(BEP)与放线菌-D(Act-D)、环磷酰胺(CTX)、甲氨蝶呤(MTX)三联序贯化疗(ACM)治疗滋养细胞肿瘤(GTN)患者的疗效及对妊娠结局的影响。【方法】选取2020年2月至2021年5月本院收治的102例GTN患者,按照随机数字表法分为BEP组(给予BEP治疗)和ACM组(给予ACM治疗),每组51例。比较两组患者临床疗效、性生活恢复时间、性功能评分、不良反应发生率、妊娠结局及治疗前后卵巢功能指标[雌二醇(E2)、黄体生成素(LH)及卵泡雌激素(FSH)]。【结果】治疗后,两组总有效率比较,差异无统计学意义(χ2=1.041,P=0.308)。治疗后,两组患者E2、LH及FSH水平均降低(P<0.05),但ACM组E2、LH及FSH水平均高于BEP组(P<0.05)。两组化疗后性生活恢复时间、性功能评分比较,差异无统计学意义(t=0.293、1.814,P=0.770、0.073)。两组不良反应总发生率比较,差异无统计学意义(χ2=1.055,P=0.316)。ACM组妊娠成功率高于BEP组(χ2=4.767,P<0.05)。【结论】BEP、ACM化疗方案治疗GTN的疗效相当,不良反应发生率接近,但ACM化疗对GTN患者的卵巢功能影响较小,有利于提高治疗后妊娠成功率。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘利英
翟瑶
张恒瑜
关键词 滋养层肿瘤/药物疗法博来霉素环磷酰胺抗肿瘤药    
Abstract:【Objective】To compare the efficacy and impact on pregnancy outcome of combination chemotherapy (BEP) with bleomycin (BLM), etoposide (VP-16), and cisplatin (DDP) with sequential chemotherapy (ACM) with actinomycin D (Act-D), cyclophosphamide (CTX), and methotrexate (MTX) in the treatment of patients with gestational trophoblastic neoplasia (GTN). 【Methods】A total of 102 patients with GTN admitted to our hospital from February 2020 to May 2021 were randomly divided into a BEP group (treated with BEP) and an ACM group (treated with ACM) according to a random number table method, with 51 patients in each group.The clinical efficacy, recovery time of sexual life, sexual function score, incidence of adverse reactions, pregnancy outcome, and ovarian function indicators [estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH)] before and after treatment were compared between the two groups. 【Results】After treatment, there was no significant difference in the total effective rate between the two groups (χ2=1.041,P=0.308). After treatment, the levels of E2, LH, and FSH in both groups decreased (P<0.05), but the levels of E2, LH, and FSH in the ACM group were higher than those in the BEP group (P<0.05). There was no significant difference in the recovery time of sexual life and sexual function score between the two groups after chemotherapy (t=0.293, 1.814, P=0.770, 0.073). The total incidence of adverse reactions in the two groups was similar (χ2=1.055, P=0.316). The pregnancy success rate in the ACM group was higher than that in the BEP group (χ2=4.767, P<0.05).【Conclusion】 The efficacy of combination chemotherapy (BEP) and sequential chemotherapy (ACM) for the treatment of gestational trophoblastic neoplasia (GTN) is comparable, and the incidence of adverse reactions is similar, but sequential chemotherapy (ACM) has less impact on the ovarian function of patients with GTN, which is beneficial to improving the pregnancy success rate after treatment.
Key wordsTrophoblastic Neoplasms/TH    Bleomycin    Cyclophosphamide    Antineoplastic Agents
收稿日期: 2023-06-25     
中图分类号:  R737.3  
通讯作者: *E-mail: 1181199652@qq.com   
引用本文:   
刘利英, 翟瑶, 张恒瑜. BEP与ACM化疗方案治疗滋养细胞肿瘤患者的疗效对比[J]. 医学临床研究, 2023, 40(12): 1885-1888.
LIU Liying,ZHAI Yao,ZHANG Hengyu. Comparison of the Efficacy of BEP and ACM Chemotherapy Regimens in the Treatment of Patients with Trophoblastic Tumors. JOURNAL OF CLINICAL RESEARCH, 2023, 40(12): 1885-1888.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.12.018     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I12/1885
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn